JP2010533722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010533722A5 JP2010533722A5 JP2010517082A JP2010517082A JP2010533722A5 JP 2010533722 A5 JP2010533722 A5 JP 2010533722A5 JP 2010517082 A JP2010517082 A JP 2010517082A JP 2010517082 A JP2010517082 A JP 2010517082A JP 2010533722 A5 JP2010533722 A5 JP 2010533722A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- ylmethoxy
- isoxazol
- dichloro
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- -1 benzoisothiazolyl Chemical group 0.000 claims 3
- BHHQDQJNIROKNF-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CCC1 BHHQDQJNIROKNF-UHFFFAOYSA-N 0.000 claims 2
- FMYIBSTZKZVLRS-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]cyclohexyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CC1 FMYIBSTZKZVLRS-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- BMHSHVMYWHJZHM-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-methylbenzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(CC1)CCN1C1=CC=C(C(O)=O)C(C)=C1 BMHSHVMYWHJZHM-UHFFFAOYSA-N 0.000 claims 1
- OLWQNBCXCFTKAN-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-phenylbenzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(CC1)CCN1C(C=1)=CC=C(C(O)=O)C=1C1=CC=CC=C1 OLWQNBCXCFTKAN-UHFFFAOYSA-N 0.000 claims 1
- TUXQDUMYSZHKDF-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-3-methylbenzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(CC1)CCN1C1=CC=C(C(O)=O)C=C1C TUXQDUMYSZHKDF-UHFFFAOYSA-N 0.000 claims 1
- SARVSQBHGLWJDC-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]benzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(CC1)CCN1C1=CC=C(C(O)=O)C=C1 SARVSQBHGLWJDC-UHFFFAOYSA-N 0.000 claims 1
- LTQORJNFRTWNQZ-UHFFFAOYSA-N 4-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]naphthalene-1-carboxylic acid Chemical compound C1CN(C=2C3=CC=CC=C3C(C(O)=O)=CC=2)CCC1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl LTQORJNFRTWNQZ-UHFFFAOYSA-N 0.000 claims 1
- KMAPTVZHJWJUDZ-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-methylbenzoic acid Chemical compound C1=C(C(O)=O)C(C)=CC(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)=C1 KMAPTVZHJWJUDZ-UHFFFAOYSA-N 0.000 claims 1
- FXODJZPFWQPPDM-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-phenylbenzoic acid Chemical compound OC(=O)C1=CC=C(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)C=C1C1=CC=CC=C1 FXODJZPFWQPPDM-UHFFFAOYSA-N 0.000 claims 1
- ZPNMRIMLACQTND-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1N1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CC1 ZPNMRIMLACQTND-UHFFFAOYSA-N 0.000 claims 1
- JDPVTPAYEUGANP-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1CCC(OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2Cl)Cl)CC1 JDPVTPAYEUGANP-UHFFFAOYSA-N 0.000 claims 1
- YLOIALRDPVKHBC-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-methylbenzoic acid Chemical compound C1=C(C(O)=O)C(C)=CC(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)OC(F)(F)F)=C1 YLOIALRDPVKHBC-UHFFFAOYSA-N 0.000 claims 1
- ITMGGFXMTLJIBH-UHFFFAOYSA-N 4-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-2-phenylbenzoic acid Chemical compound OC(=O)C1=CC=C(N2CCC(CC2)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)OC(F)(F)F)C=C1C1=CC=CC=C1 ITMGGFXMTLJIBH-UHFFFAOYSA-N 0.000 claims 1
- UVERNCKJGPCBJN-UHFFFAOYSA-N 4-[4-[[5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]benzoic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2)OC(F)(F)F)C=1COC(CC1)CCN1C1=CC=C(C(O)=O)C=C1 UVERNCKJGPCBJN-UHFFFAOYSA-N 0.000 claims 1
- QYHGTOWHHXVPJY-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-benzothiophene-3-carboxylic acid Chemical compound C1CN(C=2C=C3SC=C(C3=CC=2)C(O)=O)CCC1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl QYHGTOWHHXVPJY-UHFFFAOYSA-N 0.000 claims 1
- QEPDFQBZEHAKMC-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1CN(C=2C=C3N(C)C=C(C3=CC=2)C(O)=O)CCC1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl QEPDFQBZEHAKMC-UHFFFAOYSA-N 0.000 claims 1
- QVSRRDPHMZENOC-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=CSC2=CC=1N(CC1)CCCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl QVSRRDPHMZENOC-UHFFFAOYSA-N 0.000 claims 1
- VXDXGDBJVDCGPS-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]azepan-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1=C2N(C)C=C(C(O)=O)C2=CC=C1N(CC1)CCCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl VXDXGDBJVDCGPS-UHFFFAOYSA-N 0.000 claims 1
- GAPDATOJAODWBF-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=CSC2=CC=1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl GAPDATOJAODWBF-UHFFFAOYSA-N 0.000 claims 1
- RPVDFHPBGBMWID-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1=C2N(C)C=C(C(O)=O)C2=CC=C1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl RPVDFHPBGBMWID-UHFFFAOYSA-N 0.000 claims 1
- GWXYJEDUVAMRFV-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1=C2N(C)C=C(C(O)=O)C2=CC=C1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F GWXYJEDUVAMRFV-UHFFFAOYSA-N 0.000 claims 1
- GMKJZUNUHWUPRV-IRJFHVNHSA-N Cn1cc(C(O)=O)c2ccc(cc12)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound Cn1cc(C(O)=O)c2ccc(cc12)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 GMKJZUNUHWUPRV-IRJFHVNHSA-N 0.000 claims 1
- KLKSMSZZLBFWCT-IRJFHVNHSA-N OC(=O)c1ccc(cc1)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound OC(=O)c1ccc(cc1)[C@H]1CC[C@@H](CC1)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 KLKSMSZZLBFWCT-IRJFHVNHSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 CCC(CC*(C)[Al]C(O)=O)OCc1c(*C)[o]nc1-c1c(*)cccc1I Chemical compound CCC(CC*(C)[Al]C(O)=O)OCc1c(*C)[o]nc1-c1c(*)cccc1I 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94997407P | 2007-07-16 | 2007-07-16 | |
| US60/949,974 | 2007-07-16 | ||
| PCT/US2008/069719 WO2009012125A1 (en) | 2007-07-16 | 2008-07-11 | Compounds and methods for modulating fxr |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010533722A JP2010533722A (ja) | 2010-10-28 |
| JP2010533722A5 true JP2010533722A5 (enExample) | 2011-08-11 |
| JP5373788B2 JP5373788B2 (ja) | 2013-12-18 |
Family
ID=39855171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517082A Active JP5373788B2 (ja) | 2007-07-16 | 2008-07-11 | Ｆｘｒを調節するための化合物および方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8153624B2 (enExample) |
| EP (1) | EP2178851B1 (enExample) |
| JP (1) | JP5373788B2 (enExample) |
| KR (1) | KR101157334B1 (enExample) |
| CN (1) | CN101743232B (enExample) |
| AR (1) | AR067540A1 (enExample) |
| AT (1) | ATE539065T1 (enExample) |
| AU (1) | AU2008276236B2 (enExample) |
| BR (1) | BRPI0814571A2 (enExample) |
| CA (1) | CA2693406C (enExample) |
| CL (1) | CL2008002051A1 (enExample) |
| CO (1) | CO6270212A2 (enExample) |
| CY (1) | CY1112298T1 (enExample) |
| DK (1) | DK2178851T3 (enExample) |
| DO (1) | DOP2010000018A (enExample) |
| EA (1) | EA016475B1 (enExample) |
| EC (1) | ECSP109879A (enExample) |
| ES (1) | ES2376176T3 (enExample) |
| HR (1) | HRP20120048T1 (enExample) |
| IL (1) | IL202234A0 (enExample) |
| MA (1) | MA31683B1 (enExample) |
| MX (1) | MX2010000502A (enExample) |
| PE (1) | PE20090809A1 (enExample) |
| PL (1) | PL2178851T3 (enExample) |
| PT (1) | PT2178851E (enExample) |
| RS (1) | RS52216B (enExample) |
| SI (1) | SI2178851T1 (enExample) |
| SV (1) | SV2010003458A (enExample) |
| TN (1) | TN2010000028A1 (enExample) |
| TW (1) | TW200906823A (enExample) |
| WO (1) | WO2009012125A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289883A1 (en) * | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012087520A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2655369A1 (en) * | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| ES2846183T3 (es) | 2013-09-11 | 2021-07-28 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de la infección por el virus de la hepatitis B |
| BR112016009630B1 (pt) * | 2013-11-05 | 2021-02-09 | Novartis Ag | receptores de farnesoide x, seus usos, combinação e composição farmacêutica |
| CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| AU2016215179B2 (en) | 2015-02-06 | 2021-02-25 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| PE20180034A1 (es) | 2015-04-07 | 2018-01-09 | Intercept Pharmaceuticals Inc | Composiciones farmaceuticas para terapias combinadas |
| CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| SG11201808607SA (en) | 2016-03-28 | 2018-11-29 | Intercept Pharmaceuticals Inc | Medicine obtained by combining fxr agonist and arb |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189651A1 (en) * | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA3026512A1 (en) | 2016-06-13 | 2017-12-21 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| MA55632A (fr) * | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| KR20210110407A (ko) * | 2016-09-14 | 2021-09-07 | 노파르티스 아게 | Fxr 작용제의 신규 요법 |
| JP2019537557A (ja) * | 2016-10-04 | 2019-12-26 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法 |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
| US20210085662A1 (en) | 2017-03-30 | 2021-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| NZ758117A (en) | 2017-04-12 | 2022-01-28 | Il Dong Pharma | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
| CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
| WO2019055808A1 (en) | 2017-09-14 | 2019-03-21 | Ardelyx, Inc. | HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS |
| KR102731924B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| KR102732404B1 (ko) * | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 |
| JP7264905B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしての多環化合物 |
| SG11202003827YA (en) * | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Bridged bicyclic compounds as farnesoid x receptor modulators |
| AU2018360575A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US11667629B2 (en) | 2017-12-22 | 2023-06-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CN110452235B (zh) * | 2018-05-08 | 2023-02-17 | 中国科学院上海药物研究所 | 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途 |
| AU2018438845A1 (en) * | 2018-08-30 | 2021-04-01 | Terns Pharmaceuticals, Inc. | Treating liver disorders |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| LT3911647T (lt) | 2019-01-15 | 2024-03-25 | Gilead Sciences, Inc. | Izoksazolo junginys kaip fxr agonistas ir jį apimančios farmacinės kompozicijos |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| US12319676B2 (en) | 2019-02-15 | 2025-06-03 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
| EP3924329A2 (en) | 2019-02-15 | 2021-12-22 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| JP7465883B2 (ja) | 2019-02-15 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| SG11202111502XA (en) | 2019-04-19 | 2021-11-29 | Shanghai Institute Of Materia Medica Chinese Academy Of Sciences | Fxr small molecule agonist and preparation method therefor and use thereof |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| CA3142358A1 (en) | 2019-05-30 | 2020-12-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| US12398127B2 (en) | 2019-09-12 | 2025-08-26 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| IL292459A (en) * | 2019-11-08 | 2022-06-01 | Terns Pharmaceuticals Inc | Treatment of liver disorders |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| EP4090327B1 (en) | 2020-01-15 | 2025-03-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| EP4149452A4 (en) * | 2020-05-13 | 2024-05-01 | Terns Pharmaceuticals, Inc. | COMBINATION TREATMENT OF LIVER DISEASES |
| IL300853A (en) | 2020-08-25 | 2023-04-01 | Lilly Co Eli | Polymorphs of an ssao inhibitor |
| IL301238A (en) * | 2020-09-11 | 2023-05-01 | Terns Pharmaceuticals Inc | Solid dispersion formulations of an fxr agonist |
| EP4229043A4 (en) * | 2020-10-15 | 2025-01-08 | Eli Lilly and Company | POLYMORPHS OF AN FXR AGONIST |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| AU2022387121A1 (en) | 2021-11-11 | 2024-06-20 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| WO2023220404A1 (en) * | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| CN115850152B (zh) * | 2022-12-20 | 2025-10-31 | 河北鼎泰制药有限公司 | 一种杂质A-7-imp3的制备方法及其用途 |
| EP4568664A1 (en) | 2023-04-07 | 2025-06-18 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| JP4541883B2 (ja) | 2002-07-09 | 2010-09-08 | ブリストル−マイヤーズ スクイブ カンパニー | 抗糖尿病薬および抗肥満症薬として有用な置換へテロ環誘導体、並びに方法 |
| AU2003290700A1 (en) * | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| EP1984360B1 (en) | 2006-02-03 | 2014-01-15 | Eli Lilly & Company | Compounds and methods for modulating FX-receptors |
| PL2029547T3 (pl) * | 2006-05-24 | 2010-09-30 | Lilly Co Eli | Agoniści FXR |
| ATE460403T1 (de) * | 2006-05-24 | 2010-03-15 | Lilly Co Eli | Verbindungen und verfahren zur modulierung von fx-rezeptoren |
-
2008
- 2008-07-03 TW TW097125064A patent/TW200906823A/zh unknown
- 2008-07-11 EA EA201070148A patent/EA016475B1/ru not_active IP Right Cessation
- 2008-07-11 PE PE2008001168A patent/PE20090809A1/es not_active Application Discontinuation
- 2008-07-11 BR BRPI0814571-7A2A patent/BRPI0814571A2/pt not_active IP Right Cessation
- 2008-07-11 WO PCT/US2008/069719 patent/WO2009012125A1/en not_active Ceased
- 2008-07-11 US US12/600,879 patent/US8153624B2/en active Active
- 2008-07-11 PT PT08781651T patent/PT2178851E/pt unknown
- 2008-07-11 SI SI200830514T patent/SI2178851T1/sl unknown
- 2008-07-11 JP JP2010517082A patent/JP5373788B2/ja active Active
- 2008-07-11 HR HR20120048T patent/HRP20120048T1/hr unknown
- 2008-07-11 MX MX2010000502A patent/MX2010000502A/es active IP Right Grant
- 2008-07-11 AU AU2008276236A patent/AU2008276236B2/en not_active Ceased
- 2008-07-11 EP EP08781651A patent/EP2178851B1/en active Active
- 2008-07-11 CN CN2008800247651A patent/CN101743232B/zh active Active
- 2008-07-11 PL PL08781651T patent/PL2178851T3/pl unknown
- 2008-07-11 DK DK08781651.8T patent/DK2178851T3/da active
- 2008-07-11 AT AT08781651T patent/ATE539065T1/de active
- 2008-07-11 ES ES08781651T patent/ES2376176T3/es active Active
- 2008-07-11 RS RS20120099A patent/RS52216B/sr unknown
- 2008-07-11 KR KR1020107000896A patent/KR101157334B1/ko not_active Expired - Fee Related
- 2008-07-11 CA CA2693406A patent/CA2693406C/en not_active Expired - Fee Related
- 2008-07-14 AR ARP080103026A patent/AR067540A1/es not_active Application Discontinuation
- 2008-07-14 CL CL2008002051A patent/CL2008002051A1/es unknown
-
2009
- 2009-11-19 IL IL202234A patent/IL202234A0/en unknown
-
2010
- 2010-01-12 CO CO10002335A patent/CO6270212A2/es not_active Application Discontinuation
- 2010-01-12 DO DO2010000018A patent/DOP2010000018A/es unknown
- 2010-01-15 TN TNP2010000028A patent/TN2010000028A1/fr unknown
- 2010-01-15 EC EC2010009879A patent/ECSP109879A/es unknown
- 2010-01-15 SV SV2010003458A patent/SV2010003458A/es not_active Application Discontinuation
- 2010-02-11 MA MA32615A patent/MA31683B1/fr unknown
-
2012
- 2012-01-27 CY CY20121100098T patent/CY1112298T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010533722A5 (enExample) | ||
| JP2013519680A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| HRP20160450T1 (hr) | Novi inhibitori reduktaze s-nitrozoglutationa | |
| JP2011502982A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| JP2009538335A5 (enExample) | ||
| JP2011528658A5 (enExample) | ||
| JP2010523692A5 (enExample) | ||
| JP2012530705A5 (enExample) | ||
| JP2009535362A5 (enExample) | ||
| JP2009519965A5 (enExample) | ||
| JP2011502958A5 (enExample) | ||
| JP2016512825A5 (enExample) | ||
| JP2012510989A5 (enExample) | ||
| JP2012509263A5 (enExample) | ||
| NZ596071A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| JP2012510515A5 (enExample) | ||
| JP2004524301A5 (enExample) | ||
| JP2006517939A5 (enExample) | ||
| JP2010519243A5 (enExample) | ||
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| HRP20120048T1 (hr) | Spojevi za i postupci moduliranja fxr | |
| JP2014504646A5 (enExample) | ||
| JP2014526500A5 (enExample) |